Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05805436 · ClinicalTrials.gov registry record · Phase 4
Preop Laxatives in Robotic Urologic Surgery
A Phase 4 study of Prostate Cancer and Kidney Cancer, sponsored by Chad R. Tracy.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 240
- Enrollment target
- 1
- Study location
NCT05805436: Recruiting Phase 4 study of Prostate Cancer and Kidney Cancer, sponsored by Chad R. Tracy.
NCT05805436 is a Phase 4 study of Prostate Cancer and Kidney Cancer that is actively recruiting participants, run by Chad R. Tracy. The registered enrollment target is 240 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05805436, a Phase 4 study of Prostate Cancer and Kidney Cancer, is actively recruiting participants, sponsored by Chad R. Tracy.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 240 participants
- Enrollment target
- 1
- Study location
Study Summary
Minimally-invasive surgery, either laparoscopic or robotic, is commonly used in urology. Several urologic procedures including prostatectomy, radical nephrectomy, and partial nephrectomy are now commonly performed robotically. Patients undergoing these procedures often have delayed return of bowel function and persistent gastrointestinal symptoms including nausea/vomiting, abdominal distension, and bloating for several days to weeks after surgery. Postoperative stool softeners and laxatives are routinely used in an effort to minimize these symptoms, with varying degrees of success. The aim of this study will be to evaluate whether the use of a preoperative osmotic laxative will be beneficial in improving recovery of bowel function and alleviating postoperative gastrointestinal complaints in patients undergoing these procedures. Patients will be randomized to either receive or not receive three days of polyethylene glycol (PEG, also known as MiraLAX) on the three days before surgery. Patients in both groups will receive the same postoperative bowel regimen including scheduled PEG both in the hospital and upon discharge until first bowel movement. Patients will be given a questionnaire and diary to record their postoperative gastrointestinal symptoms and time to first bowel movement. These questionnaires and diaries will then be analyzed to determine differences in time to first bowel movement and gastrointestinal complaints during their recovery from surgery.
Primary Outcome
Time to first bowel movement after surgery
Conditions Studied
Interventions
- DRUG Polyethylene Glycol 3350
Study Locations (1)
Iowa
- University of Iowa Hospitals & Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2026-03-03 |
| Phase | Phase 4 |
What NCT05805436 shows while recruiting
NCT05805436 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (61% lower).
The record links to 3 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Polyethylene Glycol 3350 is the first listed.
NCT05805436 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT05805436 about?
NCT05805436 is a clinical study titled "Preop Laxatives in Robotic Urologic Surgery". Minimally-invasive surgery, either laparoscopic or robotic, is commonly used in urology. Several urologic procedures including prostatectomy, radical nephrectomy, and partial nephrectomy are now commonly performed robotically. Patients undergoing these procedures often have delayed return of bowel f...
What is the current status of trial NCT05805436?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 240 participants. The study started on 2023-06-01. Estimated completion is 2026-03-03.
What conditions does trial NCT05805436 study?
This clinical trial studies the following conditions: Prostate Cancer, Kidney Cancer, Constipation.
What interventions are being tested in trial NCT05805436?
The interventions under investigation include: Polyethylene Glycol 3350 (DRUG).
Who is sponsoring clinical trial NCT05805436?
This trial is sponsored by Chad R. Tracy, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05805436 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05805436's enrollment target sits among peer trials
240 193rd of 735 higher than 542 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
RECRUITING · Phase 4
-
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
RECRUITING · Phase 4
-
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
RECRUITING · Phase 4
-
Gadopiclenol in Contrast Enhanced MRI of the Prostate
RECRUITING · Phase 4
-
Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET
ACTIVE NOT RECRUITING · Phase 4
-
PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI